世界のがんCDK阻害剤市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Cancer CDK Inhibitors Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-3953
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、96ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、がんCDK阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（前臨床、フェーズI、フェーズI / II、フェーズII、フェーズIII）、用途別市場規模（医療機関、科学研究センター）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・がんCDK阻害剤の市場動向
・企業の競争状況、市場シェア
・がんCDK阻害剤の種類別市場規模と予測2016-2027（前臨床、フェーズI、フェーズI / II、フェーズII、フェーズIII）
・がんCDK阻害剤の用途別市場規模と予測2016-2027（医療機関、科学研究センター）
・がんCDK阻害剤の北米市場規模2016-2027（アメリカ、カナダ）
・がんCDK阻害剤の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・がんCDK阻害剤のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・がんCDK阻害剤の中南米市場規模2016-2027（メキシコ、ブラジル）
・がんCDK阻害剤の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Pfizer、Sanofi、Merck、Eli-Lilly、Bayer Pharmaceuticals、Syros Pharmaceuticals、Amgen、Cyclacel Pharmaceuticals）
・結論

Market Analysis and Insights: Global Cancer CDK Inhibitors Market
The global Cancer CDK Inhibitors market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cancer CDK Inhibitors market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cancer CDK Inhibitors market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cancer CDK Inhibitors market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cancer CDK Inhibitors market.

Global Cancer CDK Inhibitors Scope and Market Size
Cancer CDK Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cancer CDK Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Preclinical
Phase-I
Phase-I/II
Phase-II
Phase-III

Segment by Application
Medical Institution
Scientific Research Center

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Sanofi
Merck
Eli-Lilly
Bayer Pharmaceuticals
Syros Pharmaceuticals
Amgen
Cyclacel Pharmaceuticals

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer CDK Inhibitors Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Preclinical
1.2.3 Phase-I
1.2.4 Phase-I/II
1.2.5 Phase-II
1.2.6 Phase-III
1.3 Market by Application
1.3.1 Global Cancer CDK Inhibitors Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Medical Institution
1.3.3 Scientific Research Center
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Cancer CDK Inhibitors Market Perspective (2016-2027)
2.2 Cancer CDK Inhibitors Growth Trends by Regions
2.2.1 Cancer CDK Inhibitors Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Cancer CDK Inhibitors Historic Market Share by Regions (2016-2021)
2.2.3 Cancer CDK Inhibitors Forecasted Market Size by Regions (2022-2027)
2.3 Cancer CDK Inhibitors Industry Dynamic
2.3.1 Cancer CDK Inhibitors Market Trends
2.3.2 Cancer CDK Inhibitors Market Drivers
2.3.3 Cancer CDK Inhibitors Market Challenges
2.3.4 Cancer CDK Inhibitors Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Cancer CDK Inhibitors Players by Revenue
3.1.1 Global Top Cancer CDK Inhibitors Players by Revenue (2016-2021)
3.1.2 Global Cancer CDK Inhibitors Revenue Market Share by Players (2016-2021)
3.2 Global Cancer CDK Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Cancer CDK Inhibitors Revenue
3.4 Global Cancer CDK Inhibitors Market Concentration Ratio
3.4.1 Global Cancer CDK Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer CDK Inhibitors Revenue in 2020
3.5 Cancer CDK Inhibitors Key Players Head office and Area Served
3.6 Key Players Cancer CDK Inhibitors Product Solution and Service
3.7 Date of Enter into Cancer CDK Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Cancer CDK Inhibitors Breakdown Data by Type
4.1 Global Cancer CDK Inhibitors Historic Market Size by Type (2016-2021)
4.2 Global Cancer CDK Inhibitors Forecasted Market Size by Type (2022-2027)

5 Cancer CDK Inhibitors Breakdown Data by Application
5.1 Global Cancer CDK Inhibitors Historic Market Size by Application (2016-2021)
5.2 Global Cancer CDK Inhibitors Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Cancer CDK Inhibitors Market Size (2016-2027)
6.2 North America Cancer CDK Inhibitors Market Size by Type
6.2.1 North America Cancer CDK Inhibitors Market Size by Type (2016-2021)
6.2.2 North America Cancer CDK Inhibitors Market Size by Type (2022-2027)
6.2.3 North America Cancer CDK Inhibitors Market Size by Type (2016-2027)
6.3 North America Cancer CDK Inhibitors Market Size by Application
6.3.1 North America Cancer CDK Inhibitors Market Size by Application (2016-2021)
6.3.2 North America Cancer CDK Inhibitors Market Size by Application (2022-2027)
6.3.3 North America Cancer CDK Inhibitors Market Size by Application (2016-2027)
6.4 North America Cancer CDK Inhibitors Market Size by Country
6.4.1 North America Cancer CDK Inhibitors Market Size by Country (2016-2021)
6.4.2 North America Cancer CDK Inhibitors Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Cancer CDK Inhibitors Market Size (2016-2027)
7.2 Europe Cancer CDK Inhibitors Market Size by Type
7.2.1 Europe Cancer CDK Inhibitors Market Size by Type (2016-2021)
7.2.2 Europe Cancer CDK Inhibitors Market Size by Type (2022-2027)
7.2.3 Europe Cancer CDK Inhibitors Market Size by Type (2016-2027)
7.3 Europe Cancer CDK Inhibitors Market Size by Application
7.3.1 Europe Cancer CDK Inhibitors Market Size by Application (2016-2021)
7.3.2 Europe Cancer CDK Inhibitors Market Size by Application (2022-2027)
7.3.3 Europe Cancer CDK Inhibitors Market Size by Application (2016-2027)
7.4 Europe Cancer CDK Inhibitors Market Size by Country
7.4.1 Europe Cancer CDK Inhibitors Market Size by Country (2016-2021)
7.4.2 Europe Cancer CDK Inhibitors Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Cancer CDK Inhibitors Market Size (2016-2027)
8.2 Asia-Pacific Cancer CDK Inhibitors Market Size by Type
8.2.1 Asia-Pacific Cancer CDK Inhibitors Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Cancer CDK Inhibitors Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Cancer CDK Inhibitors Market Size by Type (2016-2027)
8.3 Asia-Pacific Cancer CDK Inhibitors Market Size by Application
8.3.1 Asia-Pacific Cancer CDK Inhibitors Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Cancer CDK Inhibitors Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Cancer CDK Inhibitors Market Size by Application (2016-2027)
8.4 Asia-Pacific Cancer CDK Inhibitors Market Size by Region
8.4.1 Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Cancer CDK Inhibitors Market Size (2016-2027)
9.2 Latin America Cancer CDK Inhibitors Market Size by Type
9.2.1 Latin America Cancer CDK Inhibitors Market Size by Type (2016-2021)
9.2.2 Latin America Cancer CDK Inhibitors Market Size by Type (2022-2027)
9.2.3 Latin America Cancer CDK Inhibitors Market Size by Type (2016-2027)
9.3 Latin America Cancer CDK Inhibitors Market Size by Application
9.3.1 Latin America Cancer CDK Inhibitors Market Size by Application (2016-2021)
9.3.2 Latin America Cancer CDK Inhibitors Market Size by Application (2022-2027)
9.3.3 Latin America Cancer CDK Inhibitors Market Size by Application (2016-2027)
9.4 Latin America Cancer CDK Inhibitors Market Size by Country
9.4.1 Latin America Cancer CDK Inhibitors Market Size by Country (2016-2021)
9.4.2 Latin America Cancer CDK Inhibitors Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Cancer CDK Inhibitors Market Size (2016-2027)
10.2 Middle East & Africa Cancer CDK Inhibitors Market Size by Type
10.2.1 Middle East & Africa Cancer CDK Inhibitors Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Cancer CDK Inhibitors Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Cancer CDK Inhibitors Market Size by Type (2016-2027)
10.3 Middle East & Africa Cancer CDK Inhibitors Market Size by Application
10.3.1 Middle East & Africa Cancer CDK Inhibitors Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Cancer CDK Inhibitors Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Cancer CDK Inhibitors Market Size by Application (2016-2027)
10.4 Middle East & Africa Cancer CDK Inhibitors Market Size by Country
10.4.1 Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Cancer CDK Inhibitors Introduction
11.1.4 Pfizer Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Cancer CDK Inhibitors Introduction
11.2.4 Sanofi Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.2.5 Sanofi Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Cancer CDK Inhibitors Introduction
11.3.4 Merck Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.3.5 Merck Recent Development
11.4 Eli-Lilly
11.4.1 Eli-Lilly Company Details
11.4.2 Eli-Lilly Business Overview
11.4.3 Eli-Lilly Cancer CDK Inhibitors Introduction
11.4.4 Eli-Lilly Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.4.5 Eli-Lilly Recent Development
11.5 Bayer Pharmaceuticals
11.5.1 Bayer Pharmaceuticals Company Details
11.5.2 Bayer Pharmaceuticals Business Overview
11.5.3 Bayer Pharmaceuticals Cancer CDK Inhibitors Introduction
11.5.4 Bayer Pharmaceuticals Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.5.5 Bayer Pharmaceuticals Recent Development
11.6 Syros Pharmaceuticals
11.6.1 Syros Pharmaceuticals Company Details
11.6.2 Syros Pharmaceuticals Business Overview
11.6.3 Syros Pharmaceuticals Cancer CDK Inhibitors Introduction
11.6.4 Syros Pharmaceuticals Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.6.5 Syros Pharmaceuticals Recent Development
11.7 Amgen
11.7.1 Amgen Company Details
11.7.2 Amgen Business Overview
11.7.3 Amgen Cancer CDK Inhibitors Introduction
11.7.4 Amgen Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.7.5 Amgen Recent Development
11.8 Cyclacel Pharmaceuticals
11.8.1 Cyclacel Pharmaceuticals Company Details
11.8.2 Cyclacel Pharmaceuticals Business Overview
11.8.3 Cyclacel Pharmaceuticals Cancer CDK Inhibitors Introduction
11.8.4 Cyclacel Pharmaceuticals Revenue in Cancer CDK Inhibitors Business (2016-2021)
11.8.5 Cyclacel Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Cancer CDK Inhibitors Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Preclinical
Table 3. Key Players of Phase-I
Table 4. Key Players of Phase-I/II
Table 5. Key Players of Phase-II
Table 6. Key Players of Phase-III
Table 7. Global Cancer CDK Inhibitors Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Cancer CDK Inhibitors Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Cancer CDK Inhibitors Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Cancer CDK Inhibitors Market Share by Regions (2016-2021)
Table 11. Global Cancer CDK Inhibitors Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Cancer CDK Inhibitors Market Share by Regions (2022-2027)
Table 13. Cancer CDK Inhibitors Market Trends
Table 14. Cancer CDK Inhibitors Market Drivers
Table 15. Cancer CDK Inhibitors Market Challenges
Table 16. Cancer CDK Inhibitors Market Restraints
Table 17. Global Cancer CDK Inhibitors Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Cancer CDK Inhibitors Market Share by Players (2016-2021)
Table 19. Global Top Cancer CDK Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer CDK Inhibitors as of 2020)
Table 20. Ranking of Global Top Cancer CDK Inhibitors Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Cancer CDK Inhibitors Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Cancer CDK Inhibitors Product Solution and Service
Table 24. Date of Enter into Cancer CDK Inhibitors Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Cancer CDK Inhibitors Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Cancer CDK Inhibitors Revenue Market Share by Type (2016-2021)
Table 28. Global Cancer CDK Inhibitors Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Cancer CDK Inhibitors Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Cancer CDK Inhibitors Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Cancer CDK Inhibitors Revenue Market Share by Application (2016-2021)
Table 32. Global Cancer CDK Inhibitors Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Cancer CDK Inhibitors Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Cancer CDK Inhibitors Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Cancer CDK Inhibitors Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Cancer CDK Inhibitors Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Cancer CDK Inhibitors Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Cancer CDK Inhibitors Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Cancer CDK Inhibitors Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Cancer CDK Inhibitors Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Cancer CDK Inhibitors Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Cancer CDK Inhibitors Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Cancer CDK Inhibitors Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Cancer CDK Inhibitors Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Cancer CDK Inhibitors Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Cancer CDK Inhibitors Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Cancer CDK Inhibitors Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Cancer CDK Inhibitors Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Cancer CDK Inhibitors Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Cancer CDK Inhibitors Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Cancer CDK Inhibitors Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Cancer CDK Inhibitors Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Cancer CDK Inhibitors Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Cancer CDK Inhibitors Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Cancer CDK Inhibitors Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Cancer CDK Inhibitors Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Cancer CDK Inhibitors Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Cancer CDK Inhibitors Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Cancer CDK Inhibitors Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2022-2027) & (US$ Million)
Table 64. Pfizer Company Details
Table 65. Pfizer Business Overview
Table 66. Pfizer Cancer CDK Inhibitors Product
Table 67. Pfizer Revenue in Cancer CDK Inhibitors Business (2016-2021) & (US$ Million)
Table 68. Pfizer Recent Development
Table 69. Sanofi Company Details
Table 70. Sanofi Business Overview
Table 71. Sanofi Cancer CDK Inhibitors Product
Table 72. Sanofi Revenue in Cancer CDK Inhibitors Business (2016-2021) & (US$ Million)
Table 73. Sanofi Recent Development
Table 74. Merck Company Details
Table 75. Merck Business Overview
Table 76. Merck Cancer CDK Inhibitors Product
Table 77. Merck Revenue in Cancer CDK Inhibitors Business (2016-2021) & (US$ Million)
Table 78. Merck Recent Development
Table 79. Eli-Lilly Company Details
Table 80. Eli-Lilly Business Overview
Table 81. Eli-Lilly Cancer CDK Inhibitors Product
Table 82. Eli-Lilly Revenue in Cancer CDK Inhibitors Business (2016-2021) & (US$ Million)
Table 83. Eli-Lilly Recent Development
Table 84. Bayer Pharmaceuticals Company Details
Table 85. Bayer Pharmaceuticals Business Overview
Table 86. Bayer Pharmaceuticals Cancer CDK Inhibitors Product
Table 87. Bayer Pharmaceuticals Revenue in Cancer CDK Inhibitors Business (2016-2021) & (US$ Million)
Table 88. Bayer Pharmaceuticals Recent Development
Table 89. Syros Pharmaceuticals Company Details
Table 90. Syros Pharmaceuticals Business Overview
Table 91. Syros Pharmaceuticals Cancer CDK Inhibitors Product
Table 92. Syros Pharmaceuticals Revenue in Cancer CDK Inhibitors Business (2016-2021) & (US$ Million)
Table 93. Syros Pharmaceuticals Recent Development
Table 94. Amgen Company Details
Table 95. Amgen Business Overview
Table 96. Amgen Cancer CDK Inhibitors Product
Table 97. Amgen Revenue in Cancer CDK Inhibitors Business (2016-2021) & (US$ Million)
Table 98. Amgen Recent Development
Table 99. Cyclacel Pharmaceuticals Company Details
Table 100. Cyclacel Pharmaceuticals Business Overview
Table 101. Cyclacel Pharmaceuticals Revenue in Cancer CDK Inhibitors Business (2016-2021) & (US$ Million)
Table 102. Cyclacel Pharmaceuticals Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer CDK Inhibitors Market Share by Type: 2020 VS 2027
Figure 2. Preclinical Features
Figure 3. Phase-I Features
Figure 4. Phase-I/II Features
Figure 5. Phase-II Features
Figure 6. Phase-III Features
Figure 7. Global Cancer CDK Inhibitors Market Share by Application: 2020 VS 2027
Figure 8. Medical Institution Case Studies
Figure 9. Scientific Research Center Case Studies
Figure 10. Cancer CDK Inhibitors Report Years Considered
Figure 11. Global Cancer CDK Inhibitors Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Cancer CDK Inhibitors Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Cancer CDK Inhibitors Market Share by Regions: 2020 VS 2027
Figure 14. Global Cancer CDK Inhibitors Market Share by Regions (2022-2027)
Figure 15. Global Cancer CDK Inhibitors Market Share by Players in 2020
Figure 16. Global Top Cancer CDK Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer CDK Inhibitors as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Cancer CDK Inhibitors Revenue in 2020
Figure 18. Global Cancer CDK Inhibitors Revenue Market Share by Type (2016-2021)
Figure 19. Global Cancer CDK Inhibitors Revenue Market Share by Type (2022-2027)
Figure 20. North America Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Cancer CDK Inhibitors Market Share by Type (2016-2027)
Figure 22. North America Cancer CDK Inhibitors Market Share by Application (2016-2027)
Figure 23. North America Cancer CDK Inhibitors Market Share by Country (2016-2027)
Figure 24. United States Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Cancer CDK Inhibitors Market Share by Type (2016-2027)
Figure 28. Europe Cancer CDK Inhibitors Market Share by Application (2016-2027)
Figure 29. Europe Cancer CDK Inhibitors Market Share by Country (2016-2027)
Figure 30. Germany Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Cancer CDK Inhibitors Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Cancer CDK Inhibitors Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Cancer CDK Inhibitors Market Share by Region (2016-2027)
Figure 40. China Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Cancer CDK Inhibitors Market Share by Type (2016-2027)
Figure 48. Latin America Cancer CDK Inhibitors Market Share by Application (2016-2027)
Figure 49. Latin America Cancer CDK Inhibitors Market Share by Country (2016-2027)
Figure 50. Mexico Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Cancer CDK Inhibitors Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Cancer CDK Inhibitors Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Cancer CDK Inhibitors Market Share by Country (2016-2027)
Figure 56. Turkey Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Cancer CDK Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Pfizer Revenue Growth Rate in Cancer CDK Inhibitors Business (2016-2021)
Figure 60. Sanofi Revenue Growth Rate in Cancer CDK Inhibitors Business (2016-2021)
Figure 61. Merck Revenue Growth Rate in Cancer CDK Inhibitors Business (2016-2021)
Figure 62. Eli-Lilly Revenue Growth Rate in Cancer CDK Inhibitors Business (2016-2021)
Figure 63. Bayer Pharmaceuticals Revenue Growth Rate in Cancer CDK Inhibitors Business (2016-2021)
Figure 64. Syros Pharmaceuticals Revenue Growth Rate in Cancer CDK Inhibitors Business (2016-2021)
Figure 65. Amgen Revenue Growth Rate in Cancer CDK Inhibitors Business (2016-2021)
Figure 66. Cyclacel Pharmaceuticals Revenue Growth Rate in Cancer CDK Inhibitors Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, Status and Forecast 2021-2027
QFJ1-5932 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、PARP（ポリADPリボースポリメラーゼ）阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（オラパリブ、タラゾパリブ）、用途別市場規模（卵巣がん、乳がん、その他）、主要地域別市場規模（北米、アメリ...

世界のBCL-2（B細胞リンパ腫2）阻害剤市場規模・現状・予測（2021年-2027年）

Global BCL-2 (B-cell lymphoma 2) Inhibitors Market Size, Status and Forecast 2021-2027
QFJ1-5611 2021年6月 85Pages
QYResearch社発行の本調査レポートでは、BCL-2（B細胞リンパ腫2）阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（併用療法、単剤療法）、用途別市場規模（がん、自己免疫疾患、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア...

世界の血管内皮増殖因子（VEGF）阻害剤市場規模・現状・予測（2021年-2027年）

Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size, Status and Forecast 2021-2027
QFJ1-6061 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、血管内皮増殖因子（VEGF）阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（VEGF-A阻害剤、VEGF-B阻害剤、VEGF-C阻害剤、VEGF-D阻害剤）、用途別市場規模（腫瘍、眼科）、主要地...

世界のHER2 (ヒト上皮成長因子受容体 2) 阻害剤市場規模・現状・予測（2021年-2027年）

Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size, Status and Forecast 2021-2027
QFJ1-4306 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、HER2 (ヒト上皮成長因子受容体 2) 阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（単剤療法、併用療法）、用途別市場規模（乳がん、胃がん、卵巣がん、その他）、主要地域別市場規模（北米、アメ...

世界のイソクエン酸デヒドロゲナーゼ阻害剤市場規模・現状・予測（2021年-2027年）

Global Isocitrate Dehydrogenase Inhibitors Market Size, Status and Forecast 2021-2027
QFJ1-4398 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、イソクエン酸デヒドロゲナーゼ阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（IDH1変異髄質悪性腫瘍、IDH2変異髄質悪性腫瘍、その他）、用途別市場規模（DH阻害剤、FLT3阻害剤、ヘッジホッグ...

世界の副腎皮質ホルモン阻害剤市場規模・現状・予測（2021年-2027年）

Global Adrenal Corticosteroid Inhibitors Market Size, Status and Forecast 2021-2027
QFJ1-3766 2021年6月 88Pages
QYResearch社発行の本調査レポートでは、副腎皮質ホルモン阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（オシロドロスタット、メチラポン）、用途別市場規模（病院、ホームケア、専門センター、その他）、主要地域別市場規模（北米、アメリカ、欧...

世界の耳がん治療市場規模・現状・予測（2021年-2027年）

Global Ear Cancer Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4169 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、耳がん治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、免疫療法、外科療法、放射線療法）、用途別市場規模（病院、診療所、外来外科センター、その他）、主要地域別市場規模（北米、アメリカ、欧州...

世界のノイラミニダーゼ阻害薬市場規模・現状・予測（2021年-2027年）

Global Neuraminidase Inhibitors Drug Market Size, Status and Forecast 2021-2027
QFJ1-5878 2021年6月 86Pages
QYResearch社発行の本調査レポートでは、ノイラミニダーゼ阻害薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（オセルタミビル、ザナミビル、ペラミビル、ラニナミビル）、用途別市場規模（病院薬局、小売薬局、オンライン薬局、その他）、主要地域別市...

世界のがんホルモン療法剤市場規模・現状・予測（2021年-2027年）

Global Cancer Hormone Therapy Drugs Market Size, Status and Forecast 2021-2027
QFJ1-3955 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、がんホルモン療法剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（タモキシフェン、アロマターゼ阻害剤、抗アンドロゲン剤、アンドロゲン合成阻害剤、その他）、用途別市場規模（乳がん、前立腺がん）、主要地域...

世界のヤヌスキナーゼ（JAK）阻害剤市場規模・現状・予測（2021年-2027年）

Global Janus Kinase (JAK) Inhibitors Market Size, Status and Forecast 2021-2027
QFJ1-5815 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、ヤヌスキナーゼ（JAK）阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ルキソリチニブ、トファシチニブ、オクラシチニブ、バリシチニブ、ペフィシチニブ）、用途別市場規模（自己免疫疾患、腫瘍）、主要...

がんCDK阻害剤のグローバル市場調査 2019年 The global Cancer CDK Inhibitors market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Cancer CDK Inhibitors volume and value at global level, regional level and company level. From a global perspective, …
世界の逆相クロマトグラフィー用カラム市場規模・現状・予測（2021年-2027年） Reversed-phase chromatography employs a polar (aqueous) mobile phase. As a result, hydrophobic molecules in the polar mobile phase tend to adsorb to the hydrophobic stationary phase, and hydrophilic molecules in the mobile phase will pass through the column and are eluted first. Market Analysis and …
がんチューブリン阻害剤のグローバル市場調査 2019年 The global Cancer Tubulin Inhibitors market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Cancer Tubulin Inhibitors volume and value at global level, regional level and company level. From a global persp…
世界のBCL-2（B細胞リンパ腫2）阻害剤市場規模・現状・予測（2021年-2027年） Bcl-2 (B-cell lymphoma 2), encoded in humans by the BCL2 gene, is the founding member of the Bcl-2 family of regulator proteins that regulate cell death (apoptosis), by either inhibiting (anti-apoptotic) or inducing (pro-apoptotic) apoptosis. Market Analysis and Insights: Global BCL-2 (B-cell lympho…
がんmTOR阻害剤のグローバル市場調査 2019年 The global Cancer mTOR Inhibitors market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Cancer mTOR Inhibitors volume and value at global level, regional level and company level. From a global perspective…